Q1 – How many patients has your Trust treated in the past 3 months for:
a. Non-small cell lung cancer (NSCLC) – any treatment
b. Non-small cell lung cancer (NSCLC) – surgical treatment
c. Non-small cell lung cancer (NSCLC) – radiotherapy
d. Non-small cell lung cancer (NSCLC) – systemic anti-cancer treatment (SACT)
Q2 – How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab monotherapy
d. Atezolizumab with chemotherapy
e. Dabrafenib + Trametinib
f. Durvalumab
g. Gemcitabine
h. Nitendanib + Docetaxel
i. Nivolumab
j. Osimertinib
k. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
l. Paclitaxel
m. Pembrolizumab monotherapy
n. Pembrolizumab with chemotherapy
o. Pemetrexed with carboplatin/cisplatin
p. RET Inhibitors (Pralsetinib, Selpercatinib)
q. Sotorasib
r. Tepotinib
s. Vinorelbine monotherapy or combination with Carboplatin/Cisplatin
t. Other active systemic anti-cancer therapy [please state]
u. Palliative care only
Q3 – Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab?
